Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000860-40
    Sponsor's Protocol Code Number:CC-220-MM-001
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2018-02-28
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2016-000860-40
    A.3Full title of the trial
    A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Une étude de phase Ib/IIa multicentrique, en ouvert, d’escalade de doses visant à déterminer la dose maximum tolérée et évaluer la sécurité d’emploi et la tolérance, la pharmacocinétique et l’efficacité préliminaire du CC-220 en monothérapie et en association avec la dexaméthasone chez les patients atteints d’un myélome multiple en rechute et réfractaire
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to decide what is the highest dose of CC-220 to take alone and with dexamethasone to assess the side effects, effectiveness and how the body deals with the drug in patients with multiple myeloma that recurs or is resistant to already tried medicines by patients.
    Une étude pour décider quelle est la dose la plus élevée de CC-220 à prendre seul et avec la dexaméthasone pour évaluer les effets indésirables, l'efficacité et la façon dont le corps traite le médicament chez les patients atteints de myélome multiple qui réapparaît ou est résistant aux médicaments déjà essayés par les patients .
    A.4.1Sponsor's protocol code numberCC-220-MM-001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCelgene Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelgene Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCelgene Corporation
    B.5.2Functional name of contact pointClinicalTrialDisclosure
    B.5.3 Address:
    B.5.3.1Street Address9224 Indian Creek Parkway, Suite 900
    B.5.3.2Town/ cityOverland Park, Kansas
    B.5.3.3Post code66210
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1888260 1599
    B.5.5Fax number+19132660394
    B.5.6E-mailClinicalTrialDisclosure@celgene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCC-220
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCC-220
    D.3.9.1CAS number 1560678-63-8
    D.3.9.2Current sponsor codeCC-220
    D.3.9.4EV Substance CodeSUB179693
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCC-220
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCC-220
    D.3.9.1CAS number 1560678-63-8
    D.3.9.2Current sponsor codeCC-220
    D.3.9.4EV Substance CodeSUB179693
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCC-220
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCC-220
    D.3.9.1CAS number 1560678-63-8
    D.3.9.2Current sponsor codeCC-220
    D.3.9.4EV Substance CodeSUB179693
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.45
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethasone tablets BP 2 mg
    D.2.1.1.2Name of the Marketing Authorisation holderAspen Pharma Trading Ltd
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namedexamethasone
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdexamethasone
    D.3.9.3Other descriptive nameDEXAMETHASONE PH. EUR.
    D.3.9.4EV Substance CodeSUB170672
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethasone-ratiopharm 4 mg tablets
    D.2.1.1.2Name of the Marketing Authorisation holderRatiopharm GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDexamethasone
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDEXAMETHASONE
    D.3.9.2Current sponsor codedexamethason-ratiopharm 4 mg
    D.3.9.4EV Substance CodeSUB07017MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCC-220
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCC-220
    D.3.9.1CAS number 1560678-63-8
    D.3.9.2Current sponsor codeCC-220
    D.3.9.4EV Substance CodeSUB179693
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCC-220
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCC-220
    D.3.9.1CAS number 1560678-63-8
    D.3.9.2Current sponsor codeCC-220
    D.3.9.4EV Substance CodeSUB179693
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    myélome multiple réfractaire et récidivant
    E.1.1.1Medical condition in easily understood language
    Multiple Myeloma that recurs or is resistant to already tried medicines by patients
    Myélome multiple qui récidive ou est résistant aux médicaments déjà essayés par les patients
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10067095
    E.1.2Term Multiple myeloma progression
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.1
    E.1.2Level HLT
    E.1.2Classification code 10028229
    E.1.2Term Multiple myelomas
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the maximum tolerated doses (MTDs) and/or recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy (MonoT) and in combination with dexamethasone (DEX) (DoubleT) in subjects with RRMM
    Déterminer les doses maximales tolérées (DMT) et/ou la dose de phase 2 recommandée (DP2R) de CC-220 en monothérapie (MonoT) et en association avec la dexaméthasone (DEX) (DoubleT) chez des patients atteints de MMRR.
    E.2.2Secondary objectives of the trial
    ·To evaluate the safety of CC-220 as MonoT and in combination with DEX (DoubleT) in subjects with RRMM
    ·To estimate the preliminary efficacy of CC-220 as MonoT and in combination with DEX (DoubleT) in subjects with RRMM
    ·To evaluate the pharmacokinetics (PK) of CC-220 in subjects with RRMM
    •Évaluer la sécurité d’emploi du CC-220 en MonoT et en association avec DEX (DoubleT) chez des patients atteints de MMRR.
    •Estimer l’efficacité préliminaire du CC-220 en MonoT et en association avec DEX (DoubleT) chez des patients atteints de MMRR.
    •Évaluer la pharmacocinétique (PK) de CC-220 chez des patients atteints de MMRR.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must satisfy the following criteria to be enrolled in the study:
    1. Subject is ≥18 years of age at the time of signing the informed consent form (ICF)
    2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
    3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements
    4. Subjects must have a documented diagnosis of MM and have measurable disease by serum and/or urine protein electrophoresis (sPEP or uPEP): sPEP ≥0.5 g/dL or uPEP ≥200 mg/24 hours
    5. All subjects must have received at least 2 prior myeloma regimens (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen)
    6. All subjects must have received prior treatment with at least 2 consecutive cycles of a lenalidomide or pomalidomide-containing regimen
    7. All subjects must have received prior treatment with at least 2 consecutive cycles of a proteasome inhibitor or a proteasome inhibitor-containing regimen
    8. For Part 2 (Cohort C and Cohort D), all subjects must have received prior treatment with at least 2 consecutive cycles of an anti-CD38 therapy or an anti-CD38-containing regimen
    9. All subjects must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy
    10. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
    11. Females of childbearing potential (FCBP) must:
    a. Have a negative pregnancy test as verified by the Investigator prior to starting CC-220. She must agree to ongoing pregnancy testing during the course of the study, and after the last dose of CC-220. This applies even if the subject practices true abstinence* from heterosexual contact.
    b. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use two forms of reliable contraception. One must be a highly effective method and one additional effective (barrier) method. Contraception must be practiced without interruption 28 days prior to initiation of CC-220, while taking CC-220 (including dose interruptions), and for at least 28 days after the last dose of CC-220.
    12. Male subjects must:
    c. Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 90 days following the last dose of CC-220, even if he has undergone a successful vasectomy.
    * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.]
    13. Males must agree to refrain from donating sperm while on CC-220, during dose
    interruptions and for at least 90 days following last dose of CC-220.
    14. All subjects must agree to refrain from donating blood while on CC-220, during dose interruption and for at least 28 days following last dose of CC-220.
    15. All male and female subjects must follow all requirements defined in the Pregnancy Prevention Program. See Appendix D of the protocol for CC-220 Pregnancy Prevention Plan for Subjects in Clinical Trials.
    Les patients doivent satisfaire les critères suivants pour pouvoir être inclus dans l’étude :
    1.Le patient est âgé d’au moins 18 ans au moment de la signature du formulaire de consentement éclairé (FCE).
    2.Le patient doit comprendre et signer volontairement un FCE avant la réalisation de toute évaluation ou procédure liée à l’étude.
    3.Le patient accepte de son plein gré et est capable de respecter le calendrier des visites d’étude et les autres exigences du protocole.
    4.Les patients doivent présenter un diagnostic documenté de MM et une maladie mesurable par électrophorèse des protéines sériques et/ou urinaires (EPPs ou EPPu) ; EPPs 0,5 g/dL ou EPPu ≥ 200 mg/24 heures.
    5.Tous les patients doivent avoir reçu au moins deux traitements antérieurs contre le myélome (note : l’induction avec ou sans transplantation de moelle osseuse et avec ou sans traitement d’entretien est considérée comme un seul traitement).
    6.Tous les patients doivent avoir reçu un traitement antérieur avec au moins deux cycles consécutifs d’un traitement contenant du lénalidomide ou du pomalidomide.
    7.Tous les patients doivent avoir reçu un traitement antérieur d’au moins 2 cycles consécutifs d’un traitement avec un inhibiteur du protéasome ou un protocole contenant un inhibiteur du protéasome.
    8.Pour la Partie 2 (cohorte C et cohorte D), tous les patients doivent avoir reçu un traitement antérieur avec au moins 2 cycles consécutifs d’un traitement anti-CD38 ou un protocole contenant un traitement anti-CD38.
    9. Tous les patients doivent présenter une progression de la maladie documentée dans les 60 jours maximum suivant la dernière dose de leur dernier traitement contre le myélome.
    10.Score de 0, 1, ou 2 à l’indice de performance de l’Eastern Cooperative Oncology Group (ECOG).
    11.Les femmes en âge de procréer (FAP) doivent :
    a.Avoir un test de grossesse négatif, vérifié par l’investigateur avant de commencer la prise de CC-220. Elles doivent accepter de passer des tests de grossesse répétés pendant le déroulement de l’étude et après avoir reçu la dernière dose de CC-220. Ceci est valable même si la patiente pratique une abstinence totale* de tout contact hétérosexuel.
    b.S’engage soit à s’abstenir totalement* de tout contact hétérosexuel (ce qui doit faire l’objet d’un contrôle mensuel et être documenté par des sources) soit à utiliser deux moyens de contraception fiables. L’un de ces moyens doit être une méthode extrêmement efficace, et l’autre une méthode efficace supplémentaire (méthode barrière). La contraception doit être pratiquée sans interruption 28 jours avant l’instauration de CC-220, lors de la prise de CC-220 (y compris les interruptions de prises) et pendant au moins 28 jours après la dernière dose de CC-220.
    12.Les patients masculins doivent :
    a.Pratiquer une abstinence totale* (devant faire l’objet d’un contrôle mensuel) ou accepter d’utiliser un préservatif pendant le contact sexuel avec une femme enceinte ou une femme en âge de procréer pendant qu’il participe à l’étude, au cours des interruptions de prises et pendant au moins 90 jours après la dernière dose de CC-220, même s’il a subi une vasectomie avec succès.
    * L’abstinence totale est acceptable lorsqu’elle est conforme au style de vie habituel et privilégié du patient. (l’abstinence périodique, c.-à-d. calendaire, ovulation, symptothermique, méthodes post-ovulation) et le retrait ne sont pas des méthodes acceptables de contraception.)
    13.Les hommes doivent accepter de ne pas faire de dons de sperme pendant qu’ils prennent le CC-220, au cours des interruptions de prises et pendant au moins 90 jours après avoir reçu la dernière dose de CC-220.
    14.Tous les patients doivent accepter de ne pas faire de don de sang pendant qu’ils prennent CC-220, au cours des interruptions de prises et pendant au moins 28 jours après avoir reçu la dernière dose de CC-220.
    15.Tous les patients (hommes et femmes) doivent se conformer à toutes les exigences définies dans le programme de prévention de la grossesse (v5.1). Voir l’Annexe D pour le Programme de prévention de la grossesse avec le CC-220 pour les patients participant à des essais cliniques.
    E.4Principal exclusion criteria
    The presence of any of the following will exclude a subject from enrollment:
    1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
    2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
    3. Subject has any condition that confounds the ability to interpret data from the study
    4. Subject has nonsecretory or oligosecretory multiple myeloma
    5. Subjects with Plasma Cell leukemia
    6. Any of the following laboratory abnormalities
    ·Absolute neutrophil count (ANC) <1,000/μL
    ·Platelet count <75,000/μL Corrected serum calcium >13.5 mg/dL (>3.4 mmol/L)
    ·Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) ≥2.0 x upper limit of normal (ULN)
    ·Serum total bilirubin and alkaline phosphatase >1.5 x ULN
    ·Subjects with serious renal impairment ([CrCl] <50 mL/min) or requiring dialysis would be excluded
    7. Subjects with peripheral neuropathy ≥Grade 2
    8. Subjects with gastrointestinal disease that may significantly alter the absorption of CC-220
    9. Subjects with a prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥5 years with the exception of the following noninvasive malignancies:
    ·Basal cell carcinoma of the skin
    ·Squamous cell carcinoma of the skin
    ·Carcinoma in situ of the cervix
    ·Carcinoma in situ of the breast
    ·Incidental histological findings of prostate cancer such as T1a or T1b using the Tumor/Node/Metastasis (TNM) classification of malignant tumors or prostate cancer that is curative
    10. Subject has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide or DEX
    11. Subject has known or suspected hypersensitivity to the excipients contained in the formulation of CC-220 or DEX
    12. Subject has received any of the following within the last 14 days of initiating IP:
    ·Plasmapheresis
    ·Major surgery (as defined by the Investigator)
    ·Radiation therapy other than local therapy for MM associated bone lesions
    ·Use of any systemic myeloma drug therapy
    13, Subject has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IP
    14. Subject has any one of the following:
    ·Clinically significant abnormal electrocardiogram (ECG) finding at Screening
    ·Congestive heart failure (New York Heart Association Class III or IV)
    ·Myocardial infarction within 12 months prior to starting IP
    ·Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris
    15. Subject has current or prior use of immunosuppressive medication within 14 days prior to the first dose of IP. The following are exceptions to this criterion:
    ·Intranasal, inhaled, topical or local steroid injections (eg, intra-articular injection)
    ·Systemic corticosteroids at physiologic doses that do not exceed 10 mg/day of prednisone or equivalent
    ·Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
    16. Subject has taken a strong inhibitor or inducer of CYP3A4/5 including
    grapefruit, St. John’s Wort or related products within two weeks prior to dosing and during the course of study.
    17. Subject known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis A or C
    18. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis
    19. Subject is a female who is pregnant, nursing or breastfeeding, or who intends to become pregnant during the participation in the study
    La présence de l’un des critères suivants empêchera l’inclusion du patient dans l’étude :
    1.Patient atteint d’une pathologie médicale, d’anomalies de laboratoire ou d’une maladie psychiatrique assez importantes pour l’empêcher de participer à l’étude.
    2.Le patient présente une affection médicale, y compris des anomalies biologiques, qui lui ferait courir un risque inacceptable au cas où il/elle participerait à l’étude.
    3.Le patient présente une affection susceptible de parasiter l’interprétation des données issues de l’étude.
    4.Le patient est atteint d’un myélome multiple non sécrétoire ou oligosécrétoire.
    5.Patients atteints de leucémie plasmocytaire.
    6.L’une des anomalies biologiques suivantes :
    •Nombre absolu de neutrophiles < 1 000/μl
    •Numération plaquettaire < 75,000/μl, calcium sérique corrigé > 13,5 mg/dl (> 3,4 mmol/l)
    •Transaminase sérique glutamique oxaloacétique (SGOT)/aspartate aminotransférase (AST) ou transaminase sérique pyruvique glutamique (SGPT)/alanine aminotransférase (ALT) ≥ 2,0 x limite supérieure de la normale (LSN)
    •Bilirubine sérique totale et phosphatase alcaline > 1,5 x LSN
    •Les patients présentant une insuffisance rénale grave ([ClCr] < 50 ml/min) ou nécessitant une dialyse seraient exclus de l’étude.
    7.Patients atteints d’une neuropathie périphérique de grade ≥ 2.
    8.Patients présentant une maladie digestive susceptible d’altérer significativement l’absorption de CC-220.
    9.Patients présentant des antécédents de malignités autres que le MM, sauf si le patient est guéri de la maladie depuis au moins 5 ans, à l’exception des malignités non invasives suivantes :
    •Carcinome cutané basocellulaire.
    •Carcinome cutané spinocellulaire (épidermoïde).
    •Carcinome in situ du col de l’utérus.
    •Carcinome in situ du sein.
    •Résultats histologiques fortuits de cancer de la prostate tels que T1a ou T1b utilisant la classification TNM (tumeur/ganglions lymphatiques/métastases) des tumeurs malignes ou cancer de la prostate guérissable.
    10.Le patient présente des antécédents d’anaphylaxie ou d’hypersensibilité au thalidomide, au lénalidomide, au pomalidomide ou au DEX.
    11.Le patient présente une hypersensibilité connue ou suspectée aux excipients contenus dans la formulation de CC-220 ou de DEX.
    12.Le patient a bénéficié de l’une des actions suivantes au cours des 14 jours après l’instauration du médicament de l’étude :
    •Plasmaphérèse
    •Intervention chirurgicale majeure (selon la définition de l’investigateur)
    •Radiothérapie autre qu’un traitement local pour des lésions osseuses associées au MM
    •Utilisation d’un traitement médicamenteux systémique contre le myélome
    13.Le patient a été traité avec un agent expérimental (c.-à-d. un agent non commercialisé) dans les 28 jours ou 5 demies vies (la durée la plus longue étant retenue) précédant le début du traitement par le médicament de l’étude.
    14.Présence de l’une des anomalies ou pathologies suivantes :
    •Anomalie cliniquement significative à l’électrocardiogramme (ECG) observée à la sélection,
    •Insuffisance cardiaque congestive (classe III ou IV de la New York Heart Association),
    •Infarctus du myocarde au cours des 12 mois précédant l’instauration du médicament de l’étude,
    •Angine de poitrine instable ou mal contrôlée, y compris angor de Prinzmetal, un type d’angine de poitrine.
    15.Le patient reçoit ou a reçu un traitement immunosuppresseur au cours des 14 jours précédant la première dose du médicament de l’étude. Exceptions à ce critère :
    •Traitement intranasal, inhalé, topique ou injections locales de corticostéroïdes (par ex. injection intra-articulaire).
    •Corticoïdes systémiques à des doses physiologiques qui n’excèdent pas 10 mg/jour de prednisone, ou équivalent.
    •Corticoïdes en prémédication à des réactions d’hypersensibilité (par ex. prémédication pour la tomodensitométrie [TDM]).
    16.Le patient a pris un puissant inhibiteur ou inducteur du CYP3A4/5, comme du pamplemousse, du millepertuis, ou des produits apparentés au cours des deux semaines précédant l’administration du médicament de l’étude et pendant le déroulement de l’étude.
    17.Patient connu pour des tests positifs pour le virus de l’immunodéficience humaine (VIH), une hépatite B chronique ou active, ou une hépatite A ou C active.
    18.Patient incapable ou refusant de se soumettre à la prophylaxie de la thromboembolie requise par le protocole.
    19.Grossesse, allaitement ou projet de grossesse d’une patiente pendant sa participation à l’étude.
    E.5 End points
    E.5.1Primary end point(s)
    Recommended Dose - Establish the maximum tolerated doses (MTDs) and or Recommended Phase 2 doses (RP2Ds) of CC-220 monotherapy and in combination with dexamethasone
    Dose recommandée: Etablir les doses maximales tolérées (DMT) et/ou la dose de phase 2 recommandée (DP2R) de CC-220 en monothérapie (MonoT) et en association avec la dexaméthasone
    E.5.1.1Timepoint(s) of evaluation of this end point
    The endpoint of MTD is estimated after cycle 1 for each subject in the dose escalation phase.

    Further details are available in the clinical study protocol and Table 4 - Table of Events page 39-42 of the protocol
    E.5.2Secondary end point(s)
    Safety - Type, frequency, seriousness and severity of adverse events (AEs) (and AEs of special interest) and relationship of AEs to investigational product
    Overall Response Rate - Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria
    Time to Response (TTR) - Time from enrollment to response (partial response [PR] or greater)
    Duration of Response - Time from the first documentation of response (PR or greater) to the first documentation of PD
    Progression-free Survival (PFS) - Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first
    Overall Survival - Time from first dose of IP to death due to any cause
    Pharmacokinetic parameters - PK of CC-220, and as appropriate, its R-enantiomer
    CC-17195 in plasma, eg, area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval (AUC0-τ), maximum plasma concentration of drug (Cmax), time to Cmax (Tmax), terminal-phase elimination half life (t1/2), apparent total plasma clearance when dosed daily (CLss/F) and apparent total volume of distribution at steady state when dosed orally (Vss/F)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety - Continuous until 28 days after the last dose of study medication.
    Overall response rate - Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Rajkumar, 2011)
    Time to response - Time from enrollment to the first documentation of response (partial response [PR] or greater)
    Duration of Response - Time from the first documentation of response (PR or greater) to the first documentation of PD
    Pharmacokinetics (intensive) - Day 8, 15 (pre-dose), 22 of Cycle 1, Day 8, 15 and 22 of Cycles 2-4.
    PK (sparse) - all pre-dose - Day 8, 15, 22 of Cycle 1, Day 8, 15 and 22 of Cycles 2-4.
    Further details are available Table 4 - Table of Events page 39-42 of the protocol
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1B/2A
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Italy
    Netherlands
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The End of Trial is defined as either the date of the last long-term follow-up data collection,, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as prespecified in the protocol, whichever is the later date.
    La fin de l’essai est définie soit par la date du dernier recueil de données du suivi à long terme ou par la date de réception du dernier point de données du dernier patient requis pour l’analyse principale, secondaire et/ou exploratoire, tel que préspécifié dans le protocole, la date la plus tardive étant retenue.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 66
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 52
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 84
    F.4.2.2In the whole clinical trial 118
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-05-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-07-03
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 23:49:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA